Dr. John (Xianfang) Zeng
Chief Executive Officer
Dr. John (Xianfang) Zeng is the CEO of Chime Biologics, assuming leadership position for company CDMO business. Chime Biologics is a leading CDMO that enables its partners’ success in biologics. With innovative R&D and manufacturing capabilities, Chime empowers the entire biologics processes from cell line development to commercialization, enabling customers to deliver innovative biologics that benefit patients worldwide.
Dr. Zeng has nearly 30 years’ experience in research, development and manufacturing of biological products. He has worked 20 years for many reputable biotechnology companies in the United States including Lonza, Shire, GlaxoSmithKline and Dendreon. In the course of his employment as technical leader and department director, he has played important roles in biologics process development, process scale-up, technology transfer, production technical support, and large-scale GMP production for more than ten commercial products (Provenge®, Synflorix®, Vpriv®, Somavert®, Replagal®, Elaprase®, ATRYN®, Increlex®, ONTAK®, Revestive®, FluViral®).
Dr. Zeng returned to China in 2012, before joining in Chime Biologics, he worked in Shanghai Zerun Biotechnology as Executive Vice President and in Yuxi Zerun Biotechnology as General Manager to lead product development, process scale-up, technology transfer, commercial plant construction, drug registration and commercial operation for multiple recombinant vaccines (such as cervical cancer vaccines, VZV vaccine and COVID-19 vaccine). Currently bivalent HPV product (WALRINVAX®) led by Dr. Zeng has successfully be approved for commercial license in China. Meanwhile, 9-valent HPV vaccine has also completed phase 3 process development and scale-up, and will soon enter phase 3 clinical study.
Dr. Zeng graduated from the State University of New York at Buffalo in USA with a Ph.D. in Biochemical Engineering under mentorship of Distinguished Professor Eli Ruckenstein (members of National Academy of Engineering, The American Academy of Arts and Sciences, and recipient of President Award in Science and Technology in USA) , and received an MBA from the University of Massachusetts at Amherst.
Dr. Zack (Zirong) Zheng
Chief Technology Officer
Senior Vice President, R&D
Dr. Zack (Zirong) Zheng, CTO and SVP, R&D of Chime Biologics, taking full responsibility for biologics process development, technology transfer and scale-up, protein analytical and formulation development, and also serves as the responsible person of Shanghai Innovation Center.
Dr. Zheng has 25 years of broad experience in biotech industry to develop therapeutic proteins, antibody drugs and vaccines in USA and China. His expertise spans from process development, technology transfer to cGMP production. He is a CMC leader with experience to develop both biosimilar and innovator drugs, and has brought multiple biologic products to market.
Previously Dr. Zheng is the co-founder and VP of DZM Biotech and VP of Jecho Biopharma. Before returning back to China 10 years ago, he held several technical and management positions as principal scientist and project manager in MedImmune, Wyeth, Pfizer with increased responsibilities.
Dr. Zheng received his bachelor degree in chemistry from Beijing Normal University, Ph.D. in chemistry from Nankai University, and did his postdoctoral training in Department of Chemistry, Aarhus University, Denmark and Department of Chemistry and Biochemistry, University of Delaware, USA.
Dr. David (Chao Hsiang) Jan
Senior Vice President, GMP Manufacturing and Engineering
Dr. David (Chao Hsiang) Jan, the Senior Vice President of Chime Biologics, is taking full responsibility of GMP clinical and commercial manufacturing, Engineering, and new plant expansion.
Dr. Jan has 30 years of experience in process development, scale up, tech transfer, and manufacturing of biological drugs, including monoclonal antibodies, fusion proteins, and nanobodies, Dr. Jan has studied and worked in Britain, Canada and the United States for many years, focusing on the process intensification and production of biological drugs and vaccines. He has participated in or led the development and commercializing of multi-billion-dollar products, such as human cytomegalovirus vaccine (HCMV, clinical stage), broad-spectrum influenza nanoparticle vaccine (clinical stage), HIV monoclonal antibody vaccine (clinical stage), Remicade® and Simponi ® (listed) for the treatment of rheumatoid and ankylosing spondylitis, Stelara® (listed) for severe psoriasis. Dr. Jan also has published more than 40 papers in internationally renowned journals such as “Biotechnology and Bioengineering”, “Glycobiology” and various international conferences.
Before joining Chime Biologics, Dr. Jan worked in the Department of Microbiology, the University of Manitoba in Canada and NIH Vaccine Research Center in United States, and also successively served as the senior scientist, project leader and department director of Cangene Biopharmaceutical in Canada, Covance Biotechnology Service Inc.,/Diosynth RTP, Johnson & Johnson, Merck in USA, SVP of Zhejiang Teruisi Pharmaceutical Inc., and SVP of Bio-Thera Solutions in China.
Dr. Jan received his doctorate in Chemical Engineering from the University of Birmingham in 1992.
Matthew (Zhigang) Luo
Senior Vice President, Quality
Matthew (Zhigang) Luo is Senior Vice President of Chime Biologics, taking full responsibility of quality management (QA and Validation, QC).
Mr. Luo gained more than 30 years of quality operation and management experience in the pharmaceutical / biotechnology industry. He has comprehensive knowledge and experience in handling daily quality issues and systematically developing quality management tools and procedures, especially in setting up the phase appropriate GMP systems. He successfully led the company through the regulatory pre-approval inspection (PAI) for commercial drug productions. Mr. Luo is an accomplished quality executive that skilled in the development, implementation and execution of quality systems.
Before joining Chime Biologics, Mr. Luo worked for Eli Lilly (USA), Amgen (USA), WuXi Biologics, Livzonmab, Mabplex and other well-known international and domestic biopharmaceutical companies and held various important positions in quality management.
Mr. Luo received a bachelor’s degree in Chemistry from Nanjing University in 1982, a master’s degree in Chemistry from University of Louisville in 1995 and an MBA from Kelley School of Business from Indiana University in 2004.
Jeffrey (Jiakuan) Chen
Vice President, HR & Admin & GA & EHS
Jeffrey (Jiakuan) Chen is Vice President of Chime Biologics, taking full responsibility of the company’s human resources strategy and planning, administrative operations, government affairs and environmental health and safety work. He also participates in the company’s investment and financing business and business development.
Mr. Chen has over 20 years’ experience in biomedical research, marketing, business, project management, capital raising, corporate senior management and operations. Before joining Chime Biologics, he served as General Manager, Senior Vice President and Marketing Director of Wuhan Optics Valley New Drug Incubation Public Service Platform Co., LTD., and also worked in Vital Pharmaceutical as Marketing Manager, R&D supervisor and other management positions. He is familiar with company operation and capital operation, and has rich experience in team building and business cooperation negotiation.
Mr. Chen obtained a Master degree in Microbiology and Biochemistry from Wuhan University.
James (Zuie-Chin) Huang
James (Zuie-Chin) Huang is the Executive Chairman of Chime Biologics, he also is Founding Managing Partner of Panacea Healthcare Venture Capital (RMB 870m Fund & USD180.5m Fund). He has devoted his passion, diligence, intelligence and loyalty into life science and investment industry over 30 years. He is a successful entrepreneur investor and an opinion leader in Venture Capital healthcare sector in China. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Since its inception in 2018, Panacea has three portfolios listed and five more submitted IPO application. Panacea is currently raising its USD Fund II with a target fund size of USD 250 million.
Mr. Huang is also Managing Partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Mr. Huang has made more than 15 investments in China since 2007.
Prior to that, Mr. Huang was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, Mr. Huang led numerous investments in China. Before joining Vivo in 2007, Mr. Huang was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
Mr. Huang is Chairman of Board at Kindstar Global, Eden Biologics and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals.
Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in Chemical Engineering from the University of California, Berkeley.
Benny (Tinlung) Chong
Benny (Tinlung) Chong has over 25 years of experience in the finance and investing industries. He has been the Chairman of VMS Group since 2006, primarily responsible for corporate planning / strategy and business development.
VMS Group of Companies is a leading multi-strategies financial services group providing individual, corporate and institutional investors with investment solutions as well as securities brokerage and corporate finance advisory services. The Group’s main operating subsidiaries, VMS Securities Ltd and VMS Asset Management Ltd, are licensed by the Securities and Futures Commission to conduct respectively (i) dealing in securities and advising on corporate finance, and (ii) advising on securities and asset management regulated activities. VMS makes and advises on investments in both private and listed equities, special and distress situations, takeovers, debts and loans.
Mr. Chong is also the Executive Chairman and CEO of Auto Italia Holdings Ltd (a company listed on the Main Board (stock code: 00720)) since 2013.
Mr. Chong has been appointed as an Executive Director, the Chairman of the Board, the Chairman of the Investment Committee and member of each of Nomination Committee and the Remuneration Committee of Newton Resources Ltd (a company listed on the Main Board (stock code: 01231)) since 2018.
Mr. Chong holds a Bachelor Degree of Commerce from the University of Toronto, Canada and a Master Degree of Science in Investment Management from the Hong Kong University of Science and Technology, Hong Kong. He obtained the qualification as a Chartered Financial Analyst from the Association for Investment Management and Research (now known as the CFA Institute) in 1997.
Andrew (Siuwai) Ng
Andrew (Siuwai) Ng has been the Head of Healthcare at VMS Group with over 13 years of healthcare industry experience spanning across management consulting, investment banking, equity research and direct investment in Greater China and the United States. He is also an Investment Partner of Panacea Venture.
Mr. Ng established the healthcare investment practice of VMS Group in 2017 and has completed multiple growth-stage investments and private equity investments across the verticals of therapeutics, diagnostics, medical devices, and CXOs. He currently sits on the board of multiple healthcare companies. Prior to joining VMS Group, Mr. Ng had been the Lead Analyst for the China Healthcare Equity Research at Barclays Capital.
Mr. Ng obtained a Bachelor of Science degree and a Master of Engineering degree from Cornell University and an MBA degree from INSEAD.
Marc Funk brings more than 20 years of leadership and industry experience in the global CDMO space. As the former CEO of Lonza Group, Mr. Funk has led the transformation and global development of Lonza Group into the world’s largest CDMO in the biotech industry. Prior to becoming the CEO of Lonza Group, Mr. Funk has been the COO and President for Lonza Pharma & Biotech.
Since 2014 Mr. Funk has transformed Lonza Pharma & Biotech by consolidating its operations all over the world and bringing its quality and operational standard to a world class level. Under his leadership Lonza Group has enjoyed seven consecutive years of rapid business growth. As a world renowned business leader, Mr. Funk has accumulated vast industry experience and deep business connections across the whole healthcare sector in Europe, North America and Far East.
Mr. Funk obtained a Master of Law and Diplomacy from Tuft University in USA and a Master of Law from University of Geneva in Switzerland.
Felix (Jiacong) Lee
Felix (Jiacong) Lee is the Head of Healthcare Investments at Chow Tai Fook Enterprises. He is also the President and CEO of UMP Healthcare China Limited and an Executive Director of UMP Healthcare Holdings. Mr. Lee also serves as an independent Non-Executive Director of China Resources Medical (HK: 1515) and Asymchem Laboratories (HK: 6821).
Mr. Lee graduated from the London School of Economics and Political Science. He is a Qualified Solicitor in Hong Kong and also serves as Vice Chairman of the China Committee, Hong Kong General Chamber of Commerce.
Connect with us
Phone +86 027 8787 9208
Chime Biologics Limited
388 Gaoxin Road (No.2)
East Lake Hi-tech Development Zone
Wuhan, Hubei Province, PRC.
Building #5, 1227 Zhangheng Road, Pudong District, Shanghai, PRC.